Tildrakizumab

What is Tildrakizumab

Tildrakizumab is an interleukin-23 antagonist indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The drug should only be given subcutaneously by a qualified health professional.

Prior to administration, all potential drug recipients must be evaluated for tuberculosis (TB) infections. DO NOT administer tildrakizumab to patients with active TB infection; patients with latent TB should initiate treatment before receiving tildrakizumab.

Brand Name

ILUMYA

Indications

  • psoriasis

For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Side Effects

  1. angioedema
  2. antibody formation
  3. bleeding
  4. diarrhea
  5. edema
  6. erythema
  7. hematoma
  8. infection
  9. injection site reaction
  10. pharyngitis
  11. pruritus
  12. urticaria

Monitoring Parameters

  • tuberculin skin test

Contraindications

  • breast-feeding
  • immunosuppression
  • infection
  • pregnancy
  • tuberculosis
  • vaccination

Interactions

  • Bacillus Calmette-Guerin Vaccine, BCG
  • Canakinumab
  • Influenza Virus Vaccine
  • Intranasal Influenza Vaccine
  • Live Vaccines
  • Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live
  • Measles/Mumps/Rubella Vaccines, MMR
  • Rotavirus Vaccine
  • Rubella Virus Vaccine Live
  • Smallpox and Monkeypox Vaccine, Live, Nonreplicating
  • Smallpox Vaccine, Vaccinia Vaccine
  • Typhoid Vaccine
  • Varicella-Zoster Virus Vaccine, Live
  • Yellow Fever Vaccine, Live
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top